Lacosamid Al

Lacosamide, the active ingredient in Lacosamid Al, is an antiepileptic presented as a tablet for oral use. It treats partial‑onset seizures as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamid Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic that acts on neuronal sodium channels to control seizure activity.

- Partial‑onset seizures: reduces seizure frequency when added to existing therapy. - Focal epilepsy: improves overall seizure control as an adjunct. - Adjunctive therapy in epilepsy: enhances seizure management alongside other antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: transient light‑headedness. - Headache: mild to moderate. - Nausea: occasional upset stomach. - Fatigue: feeling of tiredness. - Diplopia: double vision. - Blurred vision: visual disturbance.

Serious or Rare Side Effects: - Cardiac arrhythmia: PR‑interval prolongation. - Atrioventricular block: impaired heart conduction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive symptoms. - Hyponatremia: low blood sodium levels. - Liver enzyme elevation: increased transaminases.

Before prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: evaluate renal function and adjust dose if necessary. - Hepatic dysfunction: monitor liver enzymes regularly. - Cardiac conduction: obtain baseline ECG and watch for PR‑interval changes. - Pregnancy: limited data; use only when benefit outweighs potential risk. - Concomitant CNS depressants: monitor for enhanced sedation. - Store at room temperature: keep in the original container, protect from moisture.

Lacosamide can interact with other medicines, requiring attention to the interaction level.

Major Interactions (Avoid): - Carbamazepine: may reduce lacosamide plasma concentrations. - Phenytoin: may diminish lacosamide efficacy. - Strong CYP3A4 inducers: can lower lacosamide exposure.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): increased sedation risk. - Other antiepileptics (e.g., valproate): monitor plasma levels for additive effects. - Anticoagulants (e.g., warfarin): observe INR for potential changes.